1. Home
  2. PTIX vs SLRX Comparison

PTIX vs SLRX Comparison

Compare PTIX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Protagenic Therapeutics Inc.

PTIX

Protagenic Therapeutics Inc.

HOLD

Current Price

$1.41

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.67

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTIX
SLRX
Founded
1994
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.6M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
PTIX
SLRX
Price
$1.41
$0.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
93.2K
302.2K
Earning Date
11-26-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.12
$0.62
52 Week High
$14.28
$108.00

Technical Indicators

Market Signals
Indicator
PTIX
SLRX
Relative Strength Index (RSI) 37.24 26.00
Support Level $1.12 $0.62
Resistance Level $1.68 $0.72
Average True Range (ATR) 0.13 0.06
MACD 0.03 0.06
Stochastic Oscillator 35.96 7.14

Price Performance

Historical Comparison
PTIX
SLRX

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Share on Social Networks: